IBDEI1IH ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24171,2)
 ;;=^5009154
 ;;^UTILITY(U,$J,358.3,24172,0)
 ;;=L30.2^^107^1201^135
 ;;^UTILITY(U,$J,358.3,24172,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24172,1,3,0)
 ;;=3^Cutaneous Autosensitization
 ;;^UTILITY(U,$J,358.3,24172,1,4,0)
 ;;=4^L30.2
 ;;^UTILITY(U,$J,358.3,24172,2)
 ;;=^5009155
 ;;^UTILITY(U,$J,358.3,24173,0)
 ;;=L30.4^^107^1201^147
 ;;^UTILITY(U,$J,358.3,24173,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24173,1,3,0)
 ;;=3^Erythema Intertrigo
 ;;^UTILITY(U,$J,358.3,24173,1,4,0)
 ;;=4^L30.4
 ;;^UTILITY(U,$J,358.3,24173,2)
 ;;=^5009157
 ;;^UTILITY(U,$J,358.3,24174,0)
 ;;=L30.8^^107^1201^138
 ;;^UTILITY(U,$J,358.3,24174,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24174,1,3,0)
 ;;=3^Dermatitis NEC
 ;;^UTILITY(U,$J,358.3,24174,1,4,0)
 ;;=4^L30.8
 ;;^UTILITY(U,$J,358.3,24174,2)
 ;;=^5009158
 ;;^UTILITY(U,$J,358.3,24175,0)
 ;;=L30.9^^107^1201^139
 ;;^UTILITY(U,$J,358.3,24175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24175,1,3,0)
 ;;=3^Dermatitis,Unspec
 ;;^UTILITY(U,$J,358.3,24175,1,4,0)
 ;;=4^L30.9
 ;;^UTILITY(U,$J,358.3,24175,2)
 ;;=^5009159
 ;;^UTILITY(U,$J,358.3,24176,0)
 ;;=L40.0^^107^1201^293
 ;;^UTILITY(U,$J,358.3,24176,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24176,1,3,0)
 ;;=3^Psoriasis Vulgaris
 ;;^UTILITY(U,$J,358.3,24176,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,24176,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,24177,0)
 ;;=L40.1^^107^1201^296
 ;;^UTILITY(U,$J,358.3,24177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24177,1,3,0)
 ;;=3^Pustulosis Psoriasis,Generalized
 ;;^UTILITY(U,$J,358.3,24177,1,4,0)
 ;;=4^L40.1
 ;;^UTILITY(U,$J,358.3,24177,2)
 ;;=^5009161
 ;;^UTILITY(U,$J,358.3,24178,0)
 ;;=L40.2^^107^1201^12
 ;;^UTILITY(U,$J,358.3,24178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24178,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,24178,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,24178,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,24179,0)
 ;;=L40.3^^107^1201^295
 ;;^UTILITY(U,$J,358.3,24179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24179,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,24179,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,24179,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,24180,0)
 ;;=L40.4^^107^1201^160
 ;;^UTILITY(U,$J,358.3,24180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24180,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,24180,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,24180,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,24181,0)
 ;;=L40.8^^107^1201^292
 ;;^UTILITY(U,$J,358.3,24181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24181,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,24181,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,24181,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,24182,0)
 ;;=L40.9^^107^1201^294
 ;;^UTILITY(U,$J,358.3,24182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24182,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,24182,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,24182,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,24183,0)
 ;;=L50.9^^107^1201^326
 ;;^UTILITY(U,$J,358.3,24183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24183,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,24183,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,24183,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,24184,0)
 ;;=L53.8^^107^1201^150
 ;;^UTILITY(U,$J,358.3,24184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24184,1,3,0)
 ;;=3^Erythematous Conditions NEC
